Single_Cell_Gradient_3a_edited.jpg
a team with purpose
Accession Therapeutics’ mission is to eradicate cancers by harnessing the immune system more powerfully than ever before. It is built around successful biotech entrepreneurs experienced in taking projects through to the clinic. 
This team is supported by a Board comprising experienced international healthcare investors.

meet the team

management

Accession Therapeutics-61_72dpi.jpg
Ranjeet Babbra, BSc (Hons), MSc
Head of Quality Assurance (QA)  

 

Ranjeet has over 15 years’ experience of Quality Assurance across the biotechnology and pharmaceutical industry and the NHS, with significant additional experience in project management, quality management and process improvement. A Chartered Biologist, Ranjeet has numerous QA qualifications plus a BSc (Hons) and MSc from the University of Westminster. 

Dave Cole, D.Phil
Head of Molecular Science

 

Dave is a recognised expert in immune-oncology with over 13 years’ experience, including research leading to the discovery and validation of novel drug candidates plus development of collaborations with academia and industry. In his academic career Dave worked as a principal investigator and Wellcome Trust Fellow at Cardiff University, where he also carried out postdoctoral work after he received his D.Phil in Molecular Immunology from the University of Oxford.

Accession Therapeutics-52_72dpi.jpg
Accession Therapeutics-76_72dpi.jpg
Andrew ‘Jez’ Gerry, PhD
Head of Preclinical Development 

 

Jez is a leading immune-oncologist with expertise in preclinical safety and efficacy testing strategies for engineered cell therapies, engineered T cell receptors and novel immunotherapies for cancer, with over 14 years' experience at Adaptimmune Therapeutics. Jez obtained his PhD from The University of Reading in Cell and Molecular Biology.

Bent Jakobsen, PhD, FMedSci
CEO, Founder and Board Director

 

Bent is a pioneer of T cell receptor therapy for cancer with over two decades’ experience of establishing and providing scientific direction to leading T cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and prior to this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.

Accession Therapeutics-66_72dpi.jpg
Alan Parker-1_LR.jpg
Alan Parker, PhD
CSO and Founder of Trocept

 

Alan is an expert in viral gene delivery, particularly in the oncology setting, having worked in the field for almost two decades following a PhD at the University of Birmingham. He is Professor of Translational Virotherapies at the School of Medicine, Cardiff University, where his work is funded by Cancer Research UK, Cancer Research Wales and Tenovus Cancer Care amongst others. 

photo-1485939420171-378de92ecd4c_v3.jpg

board

Accession Therapeutics-15_72dpi.jpg
Nick Cross
Executive Chairman 

 

Nick is a serial entrepreneur and investor with considerable Board experience in both the biotech and high tech sectors. Nick has co-founded and served as the Chairman of a number of companies including Immunocore PLC, Adaptimmune PLC, Oxford Asymmetry International PLC (now part of Evotec) and Oxford Semiconductor Ltd (now part of Toshiba).

Bent Jakobsen, PhD, FMedSci
CEO, co-founder and Board Director

Bent is a pioneer of T cell receptor therapy for cancer with over two decades’ experience of establishing and providing scientific direction to leading T cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and prior to this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.

Accession Therapeutics-66_72dpi.jpg
Hans_bw.jpg
Hans Ivar Robinson 
Board Director 

 

Hans Ivar is a Director of Accession Therapeutics and CEO/ Chairman of Birk Venture, a Norwegian investment company focused on the life sciences sector. He brings broad industrial and investment experience from the pharmaceutical and biotechnology industry. 

Johnny Zou
Board Director

Johnny is a Director of Accession Therapeutics and Co-Head of Primavera Venture Partners, the VC arm of Primavera Capital Group, focusing on early-stage innovative tech companies in artificial intelligence, the industrial internet, and healthcare. He has led investments in some of the world’s and China’s most innovative companies in areas such as AI drug discovery, genomics and next generation immunotherapies.

Johnny Zou photo.jpg
Single_Cell_Gradient_2a.jpg
careers

Accession Therapeutics is now recruiting a world-class team to establish its R&D facility in Oxfordshire, UK.

Please go to our career page or LinkedIn page for more details.

If you are interested in joining a highly creative, dynamic and fast-developing organisation with an open, friendly non-hierarchical culture, please send your cover letters and CVs to:

joinus at accessiontherapeutics.com.

Salaries are competitive; Other benefits include pension scheme, life insurance and private health insurance.

We look forward to meeting you and discussing your future career.